Valneva SE (VALN) Non-cash Items (2021 - 2025)
Valneva SE (VALN) posted Non-cash Items of $10.8 million for Q1 2025, down 56.66% sequentially from $24.9 million in Q4 2024, and down 34.07% YoY from $16.4 million in Q1 2024.
Valneva SE (VALN) Non-cash Items (2021 - 2025) Analysis & Trends
Valneva SE has reported Non-cash Items for 5 years, with the latest figure at $10.8 million in Q1 2025.
- Quarterly Non-cash Items fell 34.07% year-over-year to $10.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$463.7 million (down 870.47% YoY) and the FY2024 annual result came in at $53.0 million, up 8.94% from the prior year.
- Non-cash Items declined to $10.8 million in Q1 2025 per VALN's latest filing, from $24.9 million in the prior quarter.
- Over five years, Non-cash Items peaked at $25.8 billion in Q2 2024 and troughed at -$26.3 billion in Q3 2024.
- A 5-year average of -$16.7 million and a median of $13.4 million in 2022 frame the typical range for Non-cash Items.
- The widest YoY moves for Non-cash Items: up 103250.28% in 2023, down 113647.48% in 2023.
- Over 5 years, Non-cash Items stood at $24.7 million in 2021, then increased by 8.41% to $26.8 million in 2022, then declined by 27.32% to $19.5 million in 2023, then rose by 27.77% to $24.9 million in 2024, then sank by 56.66% to $10.8 million in 2025.
- According to Business Quant data, Non-cash Items over the past three periods registered $10.8 million, $24.9 million, and -$26.3 billion for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 10.79 Mn |
| Mar 31, 2025 | 10.79 Mn |
| Dec 31, 2024 | 24.91 Mn |
| Dec 31, 2024 | 24.91 Mn |
| Sep 30, 2024 | -26.30 Bn |
| Sep 30, 2024 | -26.30 Bn |
| Jun 30, 2024 | 25.80 Bn |
| Jun 30, 2024 | 25.80 Bn |
| Mar 31, 2024 | 16.37 Mn |
| Mar 31, 2024 | 16.37 Mn |
| Dec 31, 2023 | 19.49 Mn |
| Dec 31, 2023 | 19.49 Mn |
| Sep 30, 2023 | -13.87 Bn |
| Sep 30, 2023 | -13.87 Bn |
| Jun 30, 2023 | 13.89 Bn |
| Jun 30, 2023 | 13.89 Bn |
| Mar 31, 2023 | 9.06 Mn |
| Mar 31, 2023 | 9.06 Mn |
| Dec 31, 2022 | 26.82 Mn |
| Dec 31, 2022 | 26.82 Mn |